Skyhawk Therapeutics, Inc., Monday announced a strategic research collaboration with Merck to develop novel small molecules that modulate RNA expression in neurological disorders with high unmet medical need.
The partnership will leverage Skyhawk's proprietary SkySTAR platform to identify small molecule candidates against RNA targets designated by Merck.
Skyhawk will oversee discovery and preclinical development, while Merck will assume responsibility for later-stage development and commercialization.
The deal is valued at over $2 billion, with Skyhawk eligible for milestone payments and tiered royalties on future sales.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.